PeptideJournal
Research16 min read

BPC-157 Systemic Effects: Multi-Organ Research

Most peptides do one thing well. BPC-157 appears to do dozens of things across nearly every organ system researchers have tested it in — from the gut lining where it was first discovered to the brain, heart, liver, and musculoskeletal tissues.

Most peptides do one thing well. BPC-157 appears to do dozens of things across nearly every organ system researchers have tested it in — from the gut lining where it was first discovered to the brain, heart, liver, and musculoskeletal tissues. That breadth is either the most interesting finding in peptide research or the biggest red flag, depending on who you ask.

Over 100 preclinical studies published since 1993 have mapped BPC-157's effects across the gastrointestinal tract, cardiovascular system, central nervous system, liver, kidneys, lungs, and connective tissues. A 2025 systematic review presented at the American College of Gastroenterology (ACG) annual meeting identified 36 studies spanning three decades of research on GI applications alone. And a February 2025 study in Medicina demonstrated that a single peptide could simultaneously protect the liver, kidneys, and lungs from ischemia-reperfusion damage in rats.

This article breaks down what the multi-organ research actually shows — organ by organ, study by study — so you can separate the data from the hype.

Important: BPC-157 is not FDA-approved for any medical condition. All evidence discussed below comes from animal studies unless otherwise noted. This article is for educational purposes and does not constitute medical advice. For background on BPC-157's origins, structure, and general pharmacology, see our BPC-157 complete guide.

Table of Contents

  1. How BPC-157 Works Across Multiple Systems
  2. Gastrointestinal Tract
  3. Cardiovascular System
  4. Central Nervous System
  5. Liver
  6. Musculoskeletal System
  7. Kidneys and Lungs
  8. The Distant Organ Protection Model
  9. What About Human Data?
  10. Limitations and Criticisms
  11. The Bottom Line
  12. References

How BPC-157 Works Across Multiple Systems

Before diving into individual organs, it helps to understand why a single peptide could plausibly affect so many different tissues. BPC-157 doesn't appear to have one narrow target. Instead, it activates pathways that are common across almost all tissue types.

The primary mechanism centers on VEGFR2 activation. A 2017 study by Hsieh et al. in the Journal of Molecular Medicine showed that BPC-157 increases both the expression and internalization of vascular endothelial growth factor receptor 2 (VEGFR2) on endothelial cells, triggering the Akt-eNOS signaling cascade that drives new blood vessel formation (Hsieh et al., 2017). In ischemic rat hind limbs, this translated to measurably increased vessel density and accelerated blood flow recovery.

A follow-up study in Scientific Reports (2020) revealed a second, independent pathway: BPC-157 also activates nitric oxide production through the Src-Caveolin-1-eNOS axis, disrupting the inhibitory complex between Caveolin-1 and eNOS to promote vasodilation directly (Hsieh et al., 2020). Phosphorylation of eNOS in endothelial cells occurred within 30 minutes of BPC-157 exposure.

What makes this mechanism particularly relevant to multi-organ effects is that every tissue in the body depends on blood supply. A peptide that rapidly promotes angiogenesis, vasodilation, and collateral blood vessel recruitment could theoretically support repair in any vascularized tissue — which is exactly what the animal data suggests.

Beyond vascular effects, BPC-157 also modulates the ERK1/2 signaling pathway, upregulates early growth response gene 1 (EGR-1) and its corepressor NAB2, engages the FAK-paxillin pathway in connective tissue repair, and interacts with both the dopaminergic and nitric oxide neurotransmitter systems. These overlapping, nonlinear pathways help explain the peptide's unusually broad preclinical profile.

Gastrointestinal Tract

The GI tract is where BPC-157 research began, and it remains the most extensively studied organ system. The peptide derives from a protective protein in human gastric juice, and unlike most peptides, it stays stable in stomach acid for over 24 hours — a property that makes oral administration uniquely feasible.

Ulcer Healing and Mucosal Protection

BPC-157 has demonstrated cytoprotective effects against virtually every type of experimental GI lesion tested. Across multiple studies from the 1990s through 2025, the peptide has prevented or healed gastric ulcers, duodenal lesions, esophageal damage, and intestinal injuries induced by alcohol, NSAIDs, restraint stress, and other insults (Sikiric et al., 2011).

A particularly compelling line of research involves NSAID-induced damage. BPC-157 counteracted gastrointestinal, liver, and brain toxicity from diclofenac when given either intraperitoneally immediately after the NSAID or orally in drinking water. Researchers have described it as a potential "antidote against NSAIDs" — capable of reversing not just the stomach damage but also the systemic toxicity these drugs produce (Sikiric et al., 2013).

Inflammatory Bowel Disease

BPC-157 reached Phase II clinical trials for inflammatory bowel disease under the designation PL 14736 (developed by Pliva, Croatia). While detailed Phase II results have not been published, multiple preclinical studies have shown efficacy in IBD models, including reduced inflammation in experimental colitis and healing of colocutaneous fistulas through nitric oxide-dependent mechanisms (Sikiric et al., 2020).

The 2025 ACG systematic review, which analyzed 36 studies from 1993 to 2025, concluded that BPC-157 "shows promise from pre-clinical studies for a range of GI pathologies — particularly in mucosal protection, wound healing, inflammatory bowel disease, and mitigation of nonsteroidal anti-inflammatory drug-induced injury" (ACG 2025, S808).

Fistula and Anastomosis Repair

In surgical models, BPC-157 accelerated the healing of ileoileal anastomoses, gastrocutaneous fistulas, duodenocutaneous fistulas, and colocutaneous fistulas in rats. One finding stood out: fistula closure occurred even when BPC-157 therapy was delayed by a full month after fistula creation (Sikiric et al., 2007).

In short-bowel syndrome models, oral and parenteral BPC-157 therapy produced immediate weight gain above preoperative values, along with increased villus height, crypt depth, and muscle thickness.

For a broader look at how BPC-157 compares to other GI-targeted peptides, see our guide on the best peptides for gut health.

Cardiovascular System

Cardiovascular research on BPC-157 reveals a pattern distinct from typical drugs: rather than pushing blood pressure or heart rate in one direction, the peptide appears to modulate these parameters toward homeostasis.

Blood Pressure Regulation

In studies using the L-NAME/L-arginine model, BPC-157 counteracted both L-NAME-induced hypertension and L-arginine-induced hypotension — moving blood pressure back toward normal regardless of which direction it had been pushed. This bidirectional effect aligns with the peptide's modulatory action on the nitric oxide system rather than a simple vasodilatory or vasoconstrictive action (Sikiric et al., 2022).

In isolated rat aortic tissue, BPC-157 produced a vasodilatory effect mediated by nitric oxide, with a 1.35-fold increase in NO production in vascular endothelial cells. Yet at typical experimental doses, tail blood pressure did not significantly differ between control and BPC-157 groups in healthy animals — suggesting the peptide corrects dysfunction rather than altering normal physiology.

Arrhythmia Prevention

BPC-157 has shown anti-arrhythmic effects across several models:

  • Digitalis toxicity: Counteracted digoxin-induced arrhythmias in rats
  • Hyperkalemia: Completely restored normal heart rhythm and electrical activity in potassium-overdose models
  • Hypokalemia: Counteracted abnormal rhythms from potassium deficiency
  • Succinylcholine toxicity: Eliminated hyperkalemia-driven arrhythmias and completely abolished post-succinylcholine hyperalgesia when given intraperitoneally or orally (Stupnisek et al., 2016)

Pulmonary Hypertension

In the monocrotaline model of pulmonary arterial hypertension — which typically produces fatal right-heart failure in rats — all BPC-157 treatment regimens counteracted the syndrome. Early treatment prevented pulmonary hypertension from developing. Even delayed treatment rapidly attenuated and "completely eliminated" established pulmonary hypertension, along with right-side heart hypertrophy and precapillary artery smooth muscle thickening (Sikiric et al., 2021).

Thrombosis

BPC-157 prevented and reversed thrombosis formation in both veins and arteries in experimental models. The peptide also maintained platelet function and activated collateral blood vessel pathways to bypass occluded vessels — a mechanism described as "upgrading minor vessels to take over the function of disabled major vessels."

Central Nervous System

The CNS data on BPC-157 spans stroke, traumatic brain injury, spinal cord compression, peripheral nerve regeneration, and various neurotransmitter disturbances. A comprehensive 2022 review in Neural Regeneration Research mapped these findings in the context of the gut-brain axis (Sikiric et al., 2022).

Stroke

In a bilateral carotid artery clamping model (mimicking ischemic stroke), BPC-157 administered during reperfusion resolved sustained neuronal damage and restored memory, locomotion, and coordination in rats. A 2020 study by Vukojevic et al. confirmed the neuroprotective effect and identified the underlying gene expression changes — upregulation of VEGFR2, Nos3, Nos1, Akt1, and EGR-1 in hippocampal tissues, with concurrent downregulation of the inflammatory Nos2 (iNOS) gene (Vukojevic et al., 2020).

Traumatic Brain Injury

In TBI models, BPC-157 preserved consciousness, reduced brain edema, decreased the number and size of hemorrhagic lacerations, mitigated subarachnoid bleeding, significantly reduced intraventricular hemorrhage, and lowered mortality. Researchers described these results as counteracting primary injury while preventing the cascade of secondary injury processes.

Spinal Cord Injury

Perovic et al. (2019) reported that a single intraperitoneal BPC-157 injection at 10 minutes after spinal cord compression counteracted tail paralysis in rats. Untreated rats showed persistent paralysis assessed over days, weeks, months, and up to a year after injury. BPC-157-treated animals showed functional recovery, reduced grey matter edema, less cyst formation and axonal necrosis in white matter, and an increased number of small axons — consistent with active regeneration (Perovic et al., 2019).

Peripheral Nerve Regeneration

BPC-157 improved sciatic nerve regeneration after transection, including in non-anastomosed models where a 7 mm gap was left between nerve ends. The peptide inserted into a tube alongside the nerve endings stimulated healing across the gap — suggesting both direct and indirect neuroprotective effects.

Neurotransmitter Modulation

BPC-157 modulates serotonergic and dopaminergic systems. It counteracted L-NAME-induced and haloperidol-induced catalepsy, and showed effects against dopamine-related disturbances. A 2024 paper in Pharmaceuticals explored these neurotransmitter interactions, positioning BPC-157's pleiotropic activity within a broader neurochemical framework (Sikiric et al., 2024).

Liver

BPC-157's hepatoprotective effects are among the most consistently demonstrated across the research literature, spanning models from acute chemical toxicity to chronic alcohol damage.

Foundational Hepatoprotection Studies

The earliest data comes from a 1993 study where BPC-157, administered intragastrically or intraperitoneally, significantly prevented liver necrosis and fatty changes in rats subjected to bile duct and hepatic artery ligation, restraint stress, and carbon tetrachloride (CCl4) administration. It outperformed all reference drugs tested, including bromocriptine, amantadine, and somatostatin. Lab values for bilirubin, SGOT, and SGPT correlated with the histological improvements (Petek et al., 1993).

Alcohol-Induced Liver Damage

In a chronic alcohol model, rats receiving 7.28 g/kg of alcohol daily for 3 months developed consistent portal hypertension and liver lesions. BPC-157 therapy both prevented these changes (prophylactic use) and reversed already-established portal hypertension and liver disturbances — even as the rats continued drinking alcohol (Prkacin et al., 2001).

In acute alcohol exposure using Robert's cytoprotection model, intragastric alcohol produced liver congestion within 1 minute and prominent hepatocyte ballooning by 30 minutes. Rats that received BPC-157 (10 ug/kg intraperitoneally, 1 minute after alcohol) showed no liver changes at the 30-minute mark.

NSAID and Paracetamol Hepatotoxicity

BPC-157 counteracted diclofenac-induced liver lesions alongside the gastrointestinal and brain damage from NSAID toxicity. Against paracetamol overdose — which produced progressive hepatic encephalopathy with generalized convulsions — BPC-157 therapy given immediately after paracetamol abolished convulsions and showed no liver lesions at 25 minutes or 3 hours, with only mild lesions at 24 hours.

Anti-Fibrotic Potential

Multiple studies report that BPC-157 counteracts the fibrotic process in liver tissue, appearing to downregulate factors that promote scarring — a finding with potential implications for chronic liver disease progression.

Musculoskeletal System

The musculoskeletal data is arguably the most clinically relevant, given that tendon and ligament injuries are the conditions most people associate with BPC-157 use. A 2025 systematic review in the Orthopaedic Journal of Sports Medicine analyzed 36 studies (35 preclinical, 1 clinical) published between 1993 and 2024 (Vasireddi et al., 2025).

Tendon Healing

BPC-157 promotes tendon repair through multiple mechanisms. It increases the outgrowth of tendon fibroblasts from explants, improves cell survival under oxidative stress (H2O2), and stimulates fibroblast migration via the FAK-paxillin pathway (Kuo et al., 2010). In Achilles tendon transection models, BPC-157 accelerated functional recovery, combining anti-inflammatory action with early blood vessel formation at the repair site (Cerovecki et al., 2008).

A particularly noteworthy molecular finding: cDNA microarray analysis revealed that growth hormone receptor was one of the most abundantly upregulated genes in BPC-157-treated tendon fibroblasts. This upregulation was dose- and time-dependent at both mRNA and protein levels, and adding growth hormone to BPC-157-treated cells further increased proliferation (Chang et al., 2014).

Muscle Healing

BPC-157 improved healing of transected quadriceps muscle and crush-injured muscle macroscopically, microscopically, functionally, and based on enzyme activity — at all investigated time intervals. It even reversed the muscle healing impairment caused by systemic corticosteroid treatment, "completely reversing" corticosteroid-impaired muscle healing (Novinscak et al., 2008; Pevec et al., 2010).

Bone Healing

In fracture models, BPC-157 promoted callus mineralization and resolution of bone defects with predominantly lamellar bone formation rather than fibrous scar tissue — performing comparably to autologous bone marrow injection and bone grafting in some measures.

For comparisons with other healing peptides, see our guides on BPC-157 vs TB-500 and BPC-157 vs GHK-Cu. Practical dosing information is available in our how to use BPC-157 guide, and for a broader perspective on joint-related applications, see best peptides for joint health.

Kidneys and Lungs

While less extensively studied than the GI tract or musculoskeletal system, the renal and pulmonary data points to BPC-157 having protective effects in these organs as well — particularly in the context of systemic injury.

Kidney Protection

In ischemia-reperfusion models, BPC-157 treatment produced significantly lower vascular and glomerular vacuolization, tubular dilation, hyaline casts, and tubular cell shedding compared to untreated controls. Antioxidant activity in kidney tissue was significantly increased, as measured by total antioxidant status (TAS), total oxidant status (TOS), oxidative stress index (OSI), and paraoxonase-1 (PON-1) levels (Gojkovic et al., 2025).

Lung Protection

In the same ischemia-reperfusion study, lung tissue in BPC-157-treated rats showed reduced interstitial edema, alveolar congestion, and total damage scores compared to controls. The anti-inflammatory and antioxidant effects were consistent with the kidney and liver findings in the same animals.

The Distant Organ Protection Model

One of the most significant recent contributions to BPC-157 research is the distant organ protection paradigm. A February 2025 study by Gojkovic et al. in Medicina tested whether BPC-157 could protect organs far from the site of original injury — specifically, whether it could shield the liver, kidneys, and lungs from damage caused by lower-extremity ischemia-reperfusion injury in rats.

The results were striking. Across all three distant organs, BPC-157 treatment:

  • Reduced histopathological damage scores
  • Decreased oxidative stress markers
  • Increased antioxidant enzyme activity
  • Mitigated inflammatory infiltration

This model matters because it mirrors real clinical scenarios. In surgery, trauma, and critical illness, ischemia-reperfusion in one body region commonly triggers multi-organ dysfunction syndrome (MODS) through systemic inflammation and oxidative stress cascades. A peptide that could attenuate this chain reaction would have obvious clinical value — though translating animal findings to human critical care is a long road.

What About Human Data?

The honest answer: very little exists. As of early 2026, only three small human studies on BPC-157 have been published.

IV Safety Pilot (2025): Lee and Burgess published the first study of intravenous BPC-157 in humans — 2 healthy adults received 10 mg on day 1 and 20 mg on day 2 via IV infusion. No adverse effects were observed. No changes in cardiac, hepatic, renal, thyroid, or metabolic biomarkers were detected. Plasma BPC-157 returned to baseline within 24 hours, consistent with its known short half-life (<30 minutes) (Lee & Burgess, 2025).

Interstitial Cystitis Pilot (2024): A private clinic study treated 12 women with severe bladder pain syndrome via direct BPC-157 injection into the bladder wall.

Knee Pain Study (2021): In 12 people with chronic knee pain, 7 reported relief lasting over 6 months after a single BPC-157 injection.

The Phase II IBD trials conducted by Pliva in Croatia (PL 14736) were described as demonstrating safety, but detailed efficacy results were never published. No registered clinical trials for BPC-157 were actively recruiting on ClinicalTrials.gov as of late 2025.

For a complete breakdown of existing clinical trial data, see our BPC-157 clinical trials database.

Limitations and Criticisms

The multi-organ research on BPC-157 is genuinely interesting. It is also genuinely limited in ways that deserve direct acknowledgment.

Single Research Group Dominance

Over 80% of all BPC-157 publications on PubMed and Google Scholar trace back to Predrag Sikiric's research group at the University of Zagreb. While Sikiric's body of work is prolific and internally consistent, the lack of independent replication from other laboratories is a significant scientific weakness. Independent groups have contributed only a handful of in vitro or short-term rodent studies.

Limited Dose-Response Data

Most experiments use only one or two doses (typically 10 ug/kg and 10 ng/kg). There is minimal data on what happens at higher, repeated, or long-term exposures — an important gap given BPC-157's short plasma half-life and the likelihood that any therapeutic use would involve chronic administration.

Animal-to-Human Translation Gap

All organ-specific findings come from rodent models. Rats are not humans. Drug candidates with strong preclinical data fail in human trials more often than they succeed, and peptides face particular challenges with bioavailability, stability, and pharmacokinetics in larger organisms.

Regulatory Status

BPC-157 is classified as a Category 2 bulk drug substance by the FDA (as of September 2023), meaning it cannot be legally compounded by pharmacies. WADA added it to its Prohibited List under S0 (Non-Approved Substances) in 2022. It has no approved therapeutic indication in any country.

Theoretical Safety Concerns

A 2025 review in Pharmaceuticals raised a specific concern: since BPC-157 upregulates VEGFR2 — a receptor active in approximately half of human cancers — the peptide could theoretically promote tumor growth if cancer cells are present. No animal studies have reported this effect, but the theoretical risk has not been formally investigated.

The Bottom Line

BPC-157's multi-organ research profile is unlike anything else in the peptide literature. Across the GI tract, cardiovascular system, CNS, liver, musculoskeletal tissues, kidneys, and lungs, animal studies show a consistent pattern: the peptide promotes angiogenesis, reduces inflammation, protects against oxidative stress, and accelerates tissue repair. The 2025 distant organ protection study adds a new dimension, showing these effects can operate systemically rather than just locally.

But the gap between "impressive animal data" and "proven human therapy" remains enormous. With only three tiny human studies published, no active clinical trials, and over 80% of the research coming from a single laboratory, BPC-157's evidence base — however consistent — falls far short of what would be needed for clinical adoption.

What the multi-organ data does establish is a biological rationale for BPC-157's broad activity. The VEGFR2-Akt-eNOS and Src-Caveolin-1-eNOS pathways are genuinely universal repair mechanisms. If the animal findings hold up in rigorous human trials, BPC-157 could represent a new class of systemic protective agent. That is a big "if" — and one that only properly designed, independently conducted clinical trials can answer.

For a broader look at BPC-157 applications, including wound healing peptides and comparative analyses like BPC-157 vs TB-500, explore our complete research library.

References

  1. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323-333. PubMed

  2. Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):17078. Nature

  3. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. PubMed

  4. Sikiric P, et al. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2013;19(1):76-83. PubMed

  5. Sikiric P, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. PMC

  6. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 as useful cytoprotective peptide therapy in the heart disturbances, myocardial infarction, heart failure, pulmonary hypertension, arrhythmias, and thrombosis presentation. Biomedicines. 2022;10(12):3106. PMC

  7. Vukojevic J, et al. The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats. Brain Behav. 2020;10(8):e01726. Wiley

  8. Perovic D, et al. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. J Orthop Surg Res. 2019;14(1):199. Springer

  9. Petek M, et al. Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. Life Sci. 1993;53(18):PL291-296. PubMed

  10. Prkacin I, et al. Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine. J Physiol Paris. 2001;95(1-6):315-324. PubMed

  11. Kuo YR, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2010;110(3):774-780. PubMed

  12. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. PMC

  13. Cerovecki T, et al. Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone. Inflamm Res. 2008;57(7):331-338. PubMed

  14. Novinscak T, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008;38(8):716-725. PubMed

  15. Pevec D, et al. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010;16(3):BR81-88. PubMed

  16. Stupnisek M, et al. BPC 157: The counteraction of succinylcholine, hyperkalemia, and arrhythmias. Eur J Pharmacol. 2016;781:83-91. PubMed

  17. Gojkovic S, et al. Protective effects of BPC 157 on liver, kidney, and lung distant organ damage in rats with experimental lower-extremity ischemia-reperfusion injury. Medicina. 2025;61(2):291. PMC

  18. Lee JW, Burgess SE. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20-24. PubMed

  19. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. Orthop J Sports Med. 2025;13(7). PMC

  20. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. J Physiol Pharmacol. 2007;58(Suppl 3):143-154. PubMed

  21. Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. PMC

  22. Sikiric P, et al. The stable gastric pentadecapeptide BPC 157 pleiotropic beneficial activity and its possible relations with neurotransmitter activity. Pharmaceuticals. 2024;17(4):461. PMC

  23. Jozwiak M, et al. Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review. Pharmaceuticals. 2025;18(2):185. MDPI

  24. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 therapy for monocrotaline-induced pulmonary hypertension in rats leads to prevention and reversal. Biomedicines. 2021;9(7):822. MDPI

  25. ACG 2025 Abstract S808. Oral peptide BPC-157 — an emerging adjunct to GI therapy. Am J Gastroenterol. 2025;120(10S2):S174. LWW